Malaria and mefloquine prophylaxis use among Japan Ground Self-Defense Force personnel deployed in East Timor.
BACKGROUND
Malaria poses a significant threat to military personnel stationed in endemic areas; therefore, it is important to examine the risks of military operations, particularly in areas where malaria-related data are scarce. The recent deployment of Japan Ground Self-Defense Force (JGSDF) for a peacekeeping operation in East Timor provided an opportunity to investigate these risks. The results of these studies may be translated into chemoprophylactic strategies for travelers.


METHODS
A total of 1,876 members were deployed between April 2002 and September 2003. They consisted of three battalions; each remained for 6 months and was put on mefloquine prophylaxis. Malaria infection was investigated, including exposure to Plasmodium falciparum sporozoites, assessed by seroconversion for anticircumsporozoite (anti-CS) protein antibodies. Adherence to and adverse events (AEs) of mefloquine were studied via questionnaires.


RESULTS
Four members were evacuated: one each with optic neuritis, lung cancer with brain metastasis, IgA nephropathy, and psychotic reactions that may have been precipitated by mefloquine. Six clinical episodes of Plasmodium vivax occurred, including one relapse, but there were no clinical cases of P falciparum, yielding a crude malaria attack rate of 0.32% for the 6-month period. Overall, 3.1% of the study population seroconverted for the anti-CS protein antibodies, with some regional differences noted. About 24% of questionnaire respondents, reported AEs; however, none of the AEs was severe. The AEs tended to emerge during the initial doses of chemoprophylaxis.


CONCLUSIONS
The implementation of mefloquine prophylaxis among JGSDF personnel in East Timor, where P falciparum constitutes a moderate risk, appears to have been a success. Mefloquine prophylaxis was generally safe for Japanese unless predisposed to neuropsychiatric illness. However, given that mefloquine is the only chemoprophylactic agent available, a risk-benefit analysis tailored to the traveler is required for visits to countries such as East Timor.
Fujii
Tatsuya
T
Department of Internal Medicine, Japan Self-Defense Forces Central Hospital, Tokyo, Japan. t-fujii@mishuku.gr.jp
Kaku
Koki
K
Jelinek
Tomas
T
Kimura
Mikio
M
D000328:Adult; D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D004363:Drug Utilization; D005260:Female; D006801:Humans; D015994:Incidence; D007564:Japan / Q000453:epidemiology; D016778:Malaria, Falciparum / Q000453:epidemiology* / Q000469:parasitology; D016780:Malaria, Vivax / Q000453:epidemiology* / Q000469:parasitology; D008297:Male; D015767:Mefloquine / Q000627:therapeutic use*; D008889:Military Personnel / Q000706:statistics & numerical data*; D010963:Plasmodium falciparum / Q000254:growth & development; D010966:Plasmodium vivax / Q000254:growth & development; D011795:Surveys and Questionnaires; D049648:Timor-Leste / Q000453:epidemiology
D000962:Antimalarials; D015767:Mefloquine